INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
65,799,000.00
-2.20 (-0.00%)
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous Close0.29
Open0.27
Bid0.00 x 800
Ask0.00 x 900
Day's Range0.25 - 0.38
52 Week Range0.14 - 11.65
Volume11,293,950
Avg. Volume5,369,234
Market Cap4,995.46T
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.60
Trade prices are not sourced from all markets
  • GlobeNewswire15 days ago

    FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose

    INSYS Therapeutics, Inc. (OTCMKTS:INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing.  INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8mg naloxone dose. “The FDA’s acceptance of the NDA for INSYS’ proprietary formulation of a naloxone nasal spray is an important milestone in battling the U.S. opioid epidemic,” said Dr. Venkat Goskonda, chief scientific officer at INSYS Therapeutics. INSYS Therapeutics is a specialty pharmaceutical company using proprietary technology and capabilities to develop and commercialize innovative pharmaceutical products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.

  • Opinion: Medical Marijuana Is a Terrible Investment
    Motley Fool28 days ago

    Opinion: Medical Marijuana Is a Terrible Investment

    Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.

  • Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
    Zackslast month

    Zynerba Up on Second Patent for Cannabidiol Candidate in 2019

    Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.

  • Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
    Zackslast month

    Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • GlobeNewswirelast month

    INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

    INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions related to the Chapter 11 petitions filed on June 10, 2019. Andrew G. Long, Chief Executive Officer of INSYS Therapeutics, Inc., said, “This is an important step forward in our court-supervised process, which is intended to fairly and transparently address the Company’s legacy legal liabilities. The Court granted INSYS interim approval to continue its existing cash management system to collect and disburse cash generated by the business.

  • Insys Down on Bankruptcy News Amid Increasing Legal Expenses
    Zackslast month

    Insys Down on Bankruptcy News Amid Increasing Legal Expenses

    Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.

  • GlobeNewswirelast month

    INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

    INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced today that INSYS has filed voluntary cases (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court in the District of Delaware (the “Court”) to facilitate the sale of substantially all of the Company’s assets and address the Company’s legacy legal liabilities. INSYS intends to continue operating its business in the ordinary course while it pursues these transactions through the court-supervised sale process.

  • 3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now
    Motley Foollast month

    3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now

    Some marijuana stocks are worth a serious look. These aren't.

  • 3 Marijuana Stocks Hitting All-Time Lows
    Motley Fool2 months ago

    3 Marijuana Stocks Hitting All-Time Lows

    Though many cannabis investors are seeing green, these pot stocks have gone up in smoke.

  • Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
    Zacks2 months ago

    Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study

    Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.

  • Why Insys Therapeutics Fell More than 70% Yesterday
    Market Realist2 months ago

    Why Insys Therapeutics Fell More than 70% Yesterday

    Why Insys Therapeutics Fell More than 70% YesterdayLiquidity positionIn its first-quarter earnings press release, which it published on May 10, Insys Therapeutics (INSY) highlighted the possibility of its being unable to continue as a going concern.

  • Why Insys Therapeutics Stock Is Crashing Today
    Motley Fool2 months ago

    Why Insys Therapeutics Stock Is Crashing Today

    The biotech raised the possibility of filing for bankruptcy in its latest earnings report.

  • CNBC2 months ago

    Drugmaker Insys shares tank after saying opioid lawsuits may force it into bankruptcy

    A Boston jury convicted Insys founder John Kapoor and four former executives of racketeering and other crimes in a fentanyl bribery case that federal prosecutors say helped fuel the U.S. opioid epidemic. Insys Therapeutics INSY shares tanked Monday morning after the company said it may have to file for bankruptcy because it can't afford legal costs related to a Department of Justice investigation into the company's sales tactics of one of its popular opioids. Insys said it had $87.6 million in cash and cash equivalents at the end of March, which falls short of the $150 million tentative settlement the company made with the Department of Justice to settle claims that the company bribed doctors to unnecessarily prescribe its fentanyl-based drug Subsys, which is meant to treat cancer patients.

  • Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today
    Motley Fool2 months ago

    Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today

    This once-promising pot stock may not survive the year.

  • Insys says it may be forced to file for bankruptcy due to litigation cash crunch
    Reuters2 months ago

    Insys says it may be forced to file for bankruptcy due to litigation cash crunch

    Insys Therapeutics Inc said on Friday that a cash crunch resulting from legal costs related to a U.S. Justice Department probe into sales practices for the company's powerful opioid medication and other litigation may lead the company to file for bankruptcy and prevent it from completing its settlement deal with the Justice Department. Insys, which has been exploring strategic options and is in talks to divest its opioid product Subsys, said it was likely that investors will lose all or a part of their investments if the company is not able to sell its assets at the value they are booked in its audited financial statements. Last August, Insys reached a tentative deal to pay at least $150 million to resolve a Department of Justice investigation into claims that the drugmaker paid doctors kickbacks to prescribe Subsys, an under-the-tongue spray that contains fentanyl, an opioid 100 times stronger than morphine.

  • Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates

    Insys Therapeutics (INSY) delivered earnings and revenue surprises of -323.08% and -48.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire2 months ago

    INSYS Therapeutics Reports First Quarter 2019 Results

    Company Continues to Execute Against Pipeline-Focused StrategyNew Drug Application Submitted for Proprietary Naloxone Nasal Spray FormulationCompany Provides Liquidity Update.

  • Market Exclusive2 months ago

    Insys Executives Found Guilty Of Bribing Doctors In Fentanyl Case

    John Kapoor and four other Insys Therapeutics Inc (NASDAQ:INSY) executives were found guilty of bribery in a racketeering case involving Fentanyl, the strongest opioid known to man. The jury presiding over the case came to a guilty verdict over the accusations presented against the Insys executives who include Kapoor, its founder and former director of […]The post Insys Executives Found Guilty Of Bribing Doctors In Fentanyl Case appeared first on Market Exclusive.

  • CNBC3 months ago

    Insys Therapeutics founder, former executives found guilty in criminal fentanyl bribery case

    A Boston jury convicted Insys Therapeutics founder John Kapoor and other former executives of racketeering and other crimes. Federal prosecutors say the fentanyl bribery case helped fuel the U.S. opioid epidemic. Prosecutors accused Kapoor and four former executives of bribing doctors to unnecessarily prescribe their painkiller, Subsys.

  • Ups and Downs in the Cannabis Space Last Week
    Market Realist3 months ago

    Ups and Downs in the Cannabis Space Last Week

    Cannabis Updates: Price Action, Ratings, and MoreCannabis spaceThe cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively, while the